The fat mass and obesity associated gene (FTO) was placed centre stage when common intronic variants within the gene were robustly associated with human obesity.
Introduction
When first cloned in 1999, Fto was postulated to have a role in programmed cell death and development. It was identified in the study of the "fused toe" (Ft) mouse, a model organism created by insertional mutagenesis that had a 1.6 Mb deletion on chromosome 8 (van der Hoeven et al., 1994) . Mice heterozygous for the Ft mutation developed fusion of the first to fourth toes of the forelimbs and thymic hyperplasia (Peters et al., 1999) . This deletion eliminated six genes (Peters et al., 2002) , three members of the Iroquois gene family (Irx3, Irx5 and Irx6) which form the IrxB cluster, as well as three other genes (Fts, Ftm and Fto) which at the time were poorly characterised. Fts was initially called "Ft1" being the first of the three to be identified: the second proved to be an elusive sequence to characterise technically so was labelled the Fantom (Ftm); the third gene was named 'Fatso' (Fto) because of its large size (Fischer et al., 2008) .
Setting a theme which plays throughout the studies of Fto biology, subsequent studies of the Ft mouse were taken up in trying to determine which of the affected genes in the larger deleted locus were responsible for the component parts of the diverse phenotypes seen in the animal. Further, these initially mysterious genes underwent name changes to reflect evolving knowledge. Ftm was found to be a novel basal body protein of cilia involved in Hedgehog (Hh) signalling . Sequence analysis revealed Ftm to be highly homologous to RPGRIP1 (retinitis pigmentosa GTPase regulator interacting protein 1, a gene encoding a protein with a role in photoreceptor cells of the eye) and it was renamed Rpgrip1-like (Rpgrip1l). In mice inactivation of Rpgrip1l causes a multi-organ syndromic phenotype with cerebral, renal and hepatic defects , while mutations in RPGRIP1L are the cause of a group of developmental disorders such as Joubert syndrome type B and Meckel syndrome (Delous et al., 2007) .
With the coming of age of technologically advanced genetic association studies, Fto underwent a more subtle but no less significant name change, with the roots of the labelling acronym reflecting its new association with obesity and metabolism.
A star is born
In the first half of 2007, three independent studies demonstrated strong association between genetic variance within FTO and human obesity. The gene name morphed into "FaT mass and Obesity associated" and the metabolic community had, at last, an example of common genetic variance with robust evidence of association with obesity in the general population.
The Frayling study initially set out to search for type 2 diabetes mellitus susceptibility genes.
In doing so they identified a common variant in the FTO gene that did indeed predispose to diabetes but through an effect on body mass index (BMI). This effect on BMI was driven entirely through fat mass and, although not detectable at birth, was fully present by the age of 7 years and persisted through adulthood (Frayling et al., 2007) . The major signal for association with BMI was a cluster of SNPs in the first intron of FTO. All BMI-associated SNPs were highly correlated with each other but SNP rs9939609, having the highest genotyping success rate, was studied further. The 16% of adults who were homozygous for the risk allele (A) weighed close to 3 kilograms more and had 1.67-fold increased odds of obesity when compared with those not inheriting a risk allele (Frayling et al., 2007) .
Complementing and confirming these findings, a contemporaneous report by Dina et al (Dina et al., 2007) took a different approach to discover this association, initially setting out to analyse the distribution of 48 neutral SNPs in a case-control obesity cohort collected from French individuals of European ancestry. While 47 of the 48 showed uniform distribution, the T allele of SNP rs 1121980 (located within the first intron of FTO) was strongly associated with severe adult obesity. Building upon this observation, Dina et al demonstrated several SNPs in the FTO locus to be highly associated not only with severe obesity in other adult, European populations but also with severe childhood obesity.
The last of this triumvirate undertook a genome-wide association study in the genetically isolated population of Sardinia to identify genetic variants associated with obesity -related quantitative traits (Scuteri et al., 2007) . Again, a number of common variants in FTO were associated with BMI, hip circumference and total body weight. The significant challenges were clear from the beginning. FTO was widely expressed throughout the body (Frayling et al., 2007) ; (Dina et al., 2007) ; (Gerken et al., 2007) and at the time nothing was know about function or potential pathways. All of these initial reports made it clear that there was no ready mechanism to explain how the predisposing intronic variants affected function or expression of FTO. Indeed, right from the start there remained the possibility that the underlying mechanism involved neighbouring genes or indeed other as yet to be identified genes more distant was raised However, hot on the heels of these initial findings, there followed a report which gave some important clues to FTO biology. Bioinformatics analysis indicated that FTO shared sequence motifs with Fe(II)-and 2-oxoglutarate-dependent oxygenases, with assays using recombinant murine Fto indeed showing that the protein could catalyze Fe(II)-and 2OG-dependent DNA demethylation, the preferred substrate being 3-methylthymine in DNA. Fto was also found to be localised to the nucleus and highly expressed in hypothalamic regions with critical roles for the control of energy balance in a nutritionally dependent manner (Gerken et al., 2007) .
Subsequently, GWAS studies for obesity-related traits in a myriad of European ancestry populations confirmed that multiple SNPs at the FTO locus were associated with BMI (Graff et al., 2013) ; (Bradfield et al., 2012) ; ; ); (Scherag et al., 2010) ; (Speliotes et al., 2010) ; ; (Wheeler et al., 2013) ; . Many other reports found the association of FTO SNPs with BMI in nonEuropean derived populations, including most populations of Asian ancestry, as well as Hispanic/Latino populations and Pima Indians (reviewed by (Loos and Yeo, 2014) ).
Studies in populations of African ancestry, in which the FTO gene shows significant differences in allele frequency and linkage disequilibrium (LD) patterns, have proven to be insightful. Although several of the previously identified variants appear not to have significant association with BMI in these populations, other intronic variation around the FTO locus (such as rs3751812, rs9941349) show strong evidence of association (Adeyemo et al., 2010) ; (Hassanein et al., 2010) . Further, the most significant value in the report by Peters et al. came from a SNP (rs56137030 ) had not been highlighted in previous studies.
( Peters et al., 2013) . A recent meta-analysis by Monda et al. of data derived from populations of African ancestry also provided support for shared BMI loci across populations (Monda et al., 2013) .
The association of FTO SNPs with obesity related traits in children and adolescents was also extended (Bradfield et al., 2012) ; ; (Scherag et al., 2010) . While SNPs in FTO did not influence birth weight (Horikoshi et al., 2013) ; (Jess et al., 2008) ; (Kilpelainen et al., 2011a) , longitudinal studies revealed the effect on body weight appeared during early childhood, reaching its peak at young adulthood (Graff et al., 2013) ; (Hardy et al., 2010) ; (Sovio et al., 2011) . This initial wave of association studies was soon followed by reports considering whether FTO SNPs associated with more specific regulators for energy homeostasis such as food intake or physical activity.
Data pointing to a link with food intake began to emerge. Obesity-associated FTO SNPs were found to be associated with increased energy intake (Cecil et al., 2008) ; (Speakman et al., 2008) ; (Timpson et al., 2008) , increased intake of dietary fat (Park et al., 2013) ; (Timpson et al., 2008) or protein (Sonestedt et al., 2009) , increased appetite and reduced satiety (Wardle et al., 2008) ; (Wardle et al., 2009 ) and loss of control over eating (Tanofsky-Kraff et al., 2009 ). This link with food intake was not seen in every study with, for example, a report by Stutzmann et al. failing to find an association of the FTO rs 1421085 C allele with eating behavious traits in a large European cohort of children and adults However, a recent GWAS of macronutrient intake in more than 70,000 individuals identified the BMI-increasing allele of FTO SNPs to be highly significantly associated with increased protein intake (Tanaka et al., 2013 ).
Other studies have consistently shown that FTO SNPs are not associated with physical activity levels (Ahmad et al., 2010) ; (Franks et al., 2008) ; (Speakman et al., 2008) ; (Vimaleswaran et al., 2009 ). However, low physical activity has been reported to accentuate the effect of FTO risk alleles on obesity in French adults ) with a largescale meta-analysis of published and unpublished data of more than 200,000 adults and 20,000 children (Kilpelainen et al., 2011b) concluding that the association of FTO SNPs with the odds of obesity are reduced by close to a third in physically active adults. Phenotypic variability in BMI for a given FTO genotype was also reported by Yang et al (Yang et al., 2012) highlighting the potential of environmental modifiers to influence the 'genetic burden' of the FTO risk alleles.
Model organisms and Fto
The phenotype of mice with a global, germline loss of Fto was first reported in 2009 (Fischer et al., 2009) . Fto null mice suffered from a high perinatal mortality and a postnatal period characterised by reduction in both body length and body weight, the latter being a result of reduced fat and lean mass. They were reported to have both an increase in food intake and an increase in metabolic rate. Later analyses of several independent murine models of Fto loss also confirmed this pattern of post-natal growth retardation but one report has shown that when corrected for alteration in body composition, there was no difference in energy expenditure in mice globally lacking Fto (McMurray et al., 2013) .
In 2010, Cox and colleagues in Harwell generated mice globally expressing additional copies of the Fto gene (Church et al., 2010) . This ubiquitous overexpression of Fto increased body and fat mass, with the obese phenotype more marked on a high-fat diet. Food intake was significantly increased, but energy expenditure and physical activity were unaltered in these mice.
Reports of more specific regional and temporal Fto perturbation soon emerged. Gao et al.
used a conditional allele to delete Fto in the nervous system (Gao et al., 2010) . Their findings that this resulted in similar phenotypes as the whole body deletion pointed to Fto having a crucial role in the central nervous system to regulate postnatal growth. Following on from the finding that Fto expression in the arcuate nucleus of the hypothalamus was nutritionally regulated (Gerken et al., 2007) ; (Stratigopoulos et al., 2011) ; (Poritsanos et al., 2011) , we targeted this region with stereotactically delivered adeno-associated virus and demonstrated that overexpression decreased food intake, while knockdown of Fto increased food intake (Tung et al., 2010) .
McMurray also used a conditional allele to globally delete Fto at 6 weeks of age.
Development in the weeks after was characterised by a loss of lean mass but an increase in fat mass (McMurray et al., 2013) . Intriguingly, regional deletion of Fto in mediobasal hypothalamus of adult mice did impact upon feeding behaviour but did not affect body composition, suggestive of Fto expressed in non-hypothalamic sites having a role in controlling lean mass.
Thus, although many questions remained unanswered, from these animal data at least it seemed plausible that Fto had a role in the regulation of body composition and energy balance.
Novel functions, unexpected roles.
How then to try and link these murine and association studies with a common molecular mechanism, particularly one involving the demethylase activity reported by Gerken et al? (Gerken et al., 2007) . The family of demethylase enzymes had long been known to have a role in repair of methyl lesions in DNA and RNA (Ougland et al., 2004) ; (Lee et al., 2005) but had little to directly link them to control of metabolism and body composition. Further studies followed that confirmed FTO catalyzed demethylation of 3-methylthymine in single-stranded DNA, as well as 3-methyluracil (3meU) (Gerken et al., 2007) ; (Jia et al., 2008) and 6-methyl adenosine (6meA) (Jia et al., 2011) in single-stranded RNA.
The crystal structure of FTO was resolved and showed an N-terminal catalytic domain and a C-terminal domain of unknown function (Han et al., 2010) . The specificity for single stranded nucleic acids appeared to come from an L1 loop, not present in other members of the AlkB family, which acted to hinder double stranded nucleic acids from entering the catalytic pocket (Han et al., 2010) .
The finding that 6meA, the most common modified nucleoside found in mRNA (Desrosiers et al., 1974) , was demethylated by FTO with 50-fold greater affinity than 3meU (Jia et al., 2011 ) gave rise to a hypothesis in which FTO influenced metabolism by post transcriptional modification of RNA message. This idea was featured in two studies in 2013 ; (Karra et al., 2013) which explored how FTO's putative demethylase action might affect complex human phenotypes.
Fto and dopamine
Hess et al ) described a role for Fto in controlling of the dopaminergic circuitry within the midbrain. The idea to explore a putative Fto-dopamine link came about because the phenotype of the Fto null mouse closely matched the description of mice lacking dopamine receptor type 2 (D2R; (Sibley, 1999) ). Their studies found that Fto null mice responded differently to control animals after administration of cocaine, a drug which can inhibit the dopamine transporter and thereby increase synaptic dopamine levels. In response to cocaine, Fto-deficient mice failed to show an increase in locomotor activity, had less c-fos activation in the ventral tegmental area (VTA), caudate putamen (CPU) and nucleus accumbens (NAc) and had a blunted increase in extracellular dopamine. Further studies administering pharmacological agents know to act through the dopaminergic system to a range of genetically engineered animals confirmed that Fto loss impairs D2R-like signalling in a cell-autonomous manner.
An elegant component to this story combined methylated RNA immunoprecipitation with bioinformatics to try and link these novel findings with previous data on the demethylase action of FTO. By identifying transcripts containing m6A in midbrains and striatum from control and Fto deficient mice, they found the transcripts selectively methylated in Fto null mice were disproportionately linked to synaptic transmission and cell signalling. Further, in the absence of Fto, both mRNA and protein of key regulators of dopaminergic neuron activity showed increased methylation.
The identification of FTO specific adenosine methylation on a subset of mRNA involved in dopamine signalling pathway was the first in vivo demonstration of FTO as a functional m6A demethylase. These observations also provided the first indication that FTO may play a tissue or even cell-type specific role by regulating specific subsets of mRNA relevant to the physiological function of the tissue, and this might help explain how a single protein can appear to have such widespread influence over a range of seemingly disparate functions.
Ghrelin and the brain; is FTO the missing link ?
The findings of the Hess study gave Fto a potential role in the reward systems. Following shortly after, a study by Karra et al. pursued a mechanistic link between FTO SNPs and gut peptides (Karra et al., 2013) . They hypothesised that FTO variants might not only influence circulating levels of hormones known to have a role in appetitive behaviour but also that they might affect the neuronal response to food cues.
Their studies focused on small numbers of young, normal weight volunteers divided into 2 matched groups on the basis of their genotype at the rs9939609 locus, either A/A (high risk) or T/T ( low risk). Compared to TT subjects, after a test meal the AA group were reported to have a less marked fall in acyl ghrelin and an attenuated suppression in a visual analogue hunger score.
Analysis of mRNA from peripheral blood cells after a period of fasting was showed that subjects with the AA genotype had, in comparison to the TT group, a 1.5 fold increase in FTO expression, a 2.5 fold increase in ghrelin precursor GHRL mRNA abundance and a reduction in m6 A methylation of ghrelin mRNA. Functional MRI (fMRI) analysis showed between-genotype differences in a number of brain regions recognised to have roles in energy homeostasis and reward related activity.
A further potential link to ghrelin was suggested by data from in vitro studies, where FTO overexpression increased not only ghrelin and ghrelin O-acyltransferase (GOAT) mRNA but also total and acyl ghrlein concentrations in cell lysates. FTO overexpression was also reported to reduce m6 A methylation of ghrelin mRNA. 
Loss-of -function mutations in humans
Despite all these emerging data, there remained the recurring uncertainty of what these findings brought to our greater understanding of human disease, the primary driver for undertaking the genetic studies in the first place.
Important data on the potential consequences of FTO loss in humans came from a study of a consanguineous family in which affected individuals presented with a previously unreported autosomal-recessive syndrome characterised by polymalformation and childhood mortality (Boissel et al., 2009 ) . Genome-wide autozygosity screening identified a unique region of shared homozygosity on chromosome 16q12. Further genotype and haplotype analyses reduced the critical region to a 6.5Mb interval encompassing 28 genes. After sequencing coding regions and splice junctions of all known and putative genes in this linked region, the only mutation found was a homozygous single-nucleotide variation at cDNA position 947 within the FTO gene. Affected individuals carried a homozygous R316Q mutation in FTO, with loss of this highly conserved arginine residue rendering FTO enzymatically null in two different in vitro assays; the first based on the conversion of the 2-oxoglutarate to succinate and the second on the ability of FTO to demethylate 3-methylthymine in DNA. The affected individuals homozygous for a catalytically inactive FTO also had, like Fto null mice, an early growth retardation phenotype but, unlike the Fto null mice, also had developmental abnormalities in the central nervous or cardiovascular systems. These differences are not readily explained and the molecular mechanisms whereby the mutant FTO leads to the severe phenotype observed these patients remain unknown. However, it may be the point mutation in FTO has deleterious "gain-of-function" effects and/or dominant-negative interference with other biochemical processes that are not seen with the complete deficiency seen in Fto null mouse.
What of other members of this extended family? Fto +/-mice were considered to be resistant to diet induced obesity (Fischer et al., 2009) , so could heterozygous carriage of this deleterious R316Q mutation actually protect against obesity? This also remains uncertain because, although this report comments that none of the parents of affected children, obese but detailed phenotypic data on the extended family has not been reported.
Other studies have gone on to look whether nonsynonymous variants of FTO might be enriched in either lean or obese subjects. Meyre et al. sequenced entire FTO coding regions in both subjects with severe obesity and in individuals with lifelong leanness (Meyre et al., 2010) .Interestingly, non-synonymous mutations were equally common in both the obese and lean cohorts. Further, heterozygous mutations that severely impaired enzymatic activity of FTO were found in both lean and obese subjects who were otherwise clinically unremarkable.
Other studies in lean and obese cohorts of children brought similar findings. In both African
American and Chinese Han populations, variants were identified in FTO but the overall frequencies were similar in case and control with none conferring risk of obesity (Deliard et al., 2013) ; (Zheng et al., 2013) .
Taken in isolation, these human data fall some way short of a compelling case for FTO being the candidate mediator of the obesity association. Murine data indicate that an increase in Fto expression could potentially lead to obesity but, to date, only deleterious point mutations have been described in obese patients. However, it may be that there are as yet uncharacterised patients in other cohorts with genetically deleterious mutations leading to complete loss of FTO. For example, such an individual may, if they were to phenocopy the mouse model of Fto deficiency, present initially as a "failure to thrive" and thereafter be noted to be of small stature.
An interesting neighbourhood
As outlined above, the initial FTO intronic associations, followed by identification of association SNPs in intron 3 (Tonjes et al., 2010) and intron 8 (Adeyemo et al., 2010) , set in train a plethora of studies based around Fto biology. However, other groups took a different path, with the Leibel group in particular choosing to focus upon Rpgrip1l as being the potential mechanistic link. They initially took an in silico bioinformatics approach to focus on twointronic SNPs (rs17817449 and rs8050136) and predicted they were located in a putative binding site for the transcription factor Cutl-like 1 (CUTL1), also known as cut-like homeobox1 (CUX1) (Stratigopoulos et al., 2008) . CUTL1 acts as a transcriptional repressor by displacing activators (Skalnik et al., 1991) and/or by recruitment of histone deacetylase 1 (Mailly et al., 1996) . Initial in vitro data were promising. In ChIP of DNA from human fibroblasts using a CUTL1-specific antibody, a 90-bp fragment that included rs8050136 was precipitated. Further, siRNA mediated reduction of Cutl1 by 70% resulted in FTO expression decreasing by 90% and FTM by 65%.
Having raised the possibility that both genes were regulated by a CUTL1/CUX1 via a single regulatory site in the first intron of FTO, Leibel's group went on to look in more detail at the role on the different isoforms of this transcription factor (larger P200 and the smaller p100 isoform, generated from p200 by enzymatic cathepsin L activity) (Stratigopoulos et al., 2011) .
A series of detailed biochemical and promoter analysis experiments lead to a proposed mechanism whereby together FTO, RPGRIP1L, and CUX1 facilitate the leptin response within the hypothalamic arcuate nucleus and thereby affect food intake. The model proposed that reduced circulating leptin, as seen in negative energy balance, results in reduced enzymatic processing of CUX1 P200 and decreased CUX1 P110 protein levels. This change in transcription factor isoform ratio in turn decreases RPGRIP1L and FTO expression, reducing leptin signaling through an alteration in leptin receptor recruitment at the cilium and thereby increasing the drive to eat. The proposed model goes on to suggest that because P110 has reduced affinity for the rs8050136 obesity-risk (A) allele but higher affinity for the protective (C) allele, individuals with the C allele would have higher FTO and RPGRIP1L expression and be relatively more leptin sensitive (Fig 1A) Building upon their previous findings, this group have more recently published a detailed metabolic phenotype of mice lacking one copy of Rpgrip1l (Stratigopoulos et al., 2014) . As noted previously, homozygous mutations in Rpgrip1l lead to significant developmental anomalies , but Rpgrip1l +/-mice had a small but statistically significant 10% increase in body weight demonstrable by 10 week (Fig 1B) . Analysis of older animals showed this to be driven by increase in fat but not lean mass. By 19 weeks old, male mice had an increase in both fat and lean mass with absolute food intake corrected for different body compositions showing Rpgrip1l +/-to be hyperphagic.
In Rpgrip1l
+/-mice, an acute leptin dose was reported to show a diminished Stat 3 response within the hypothalamus and an antibody based analysis showed a reduction of leptin receptor in the vicinity of the cilia.
This group went on to look at fibroblasts from healthy human controls and from a patient with Jouberts syndrome to furtherdetermine how RPGRIP1Linteracts with the leptin receptor. When leptin receptors were transfected into control fibroblasts, they correctly localized to the cilium with leptin stimulation and there was a dose dependent increase in Stats 3 phosphorylation. In contrast there was both perturbed localisation and diminished signalling in RPGRIP1L deficient fibroblasts.
They concluded that alteration in leptin receptors signaling brought about as a direct consequence of alteration in the function of primary cilium accounted for the increase in fat mass of Rpgrip1l +/-mice. These model organism studies are presented as further supportive evidence that individuals with obesity risk A allele at rs 8050136 have reduction in both RPGRIP1L and FTO expression due to reduction on p110 at cognate CUX1 binding causing diminished leptin signalling, increased food intake and adiposity.
Disorders of ciliary biology have long been linked to "syndromic obesity" and these data from the Liebel group now raise the intriguing possibility of primary cilia having a role in common forms of obesity. However, there remains still that elusive, direct connection between obesity associated variants and expression of the gene in question, in particular whether in humans the number of copies of the risk allele associates with changes of expression of RPGRIP1L and FTO not only in the direction predicted by the model but also in physiologically relevant tissue.
IRX3-another interesting neighbour.
Irx3 was one of the initial genes identified within the Ft region, but initially did not attract as much attention as its neighbours. A report by Ragvin (Ragvin et al., 2010) re-ignited interest in its relationship with FTO. This group focussed in on the fact that the FTO LD block appeared to contain numerous highly conserved non coding elements (HCNEs) and used computational analysis to determine if these potential regulatory elements might affect target genes elsewhere.
Their initial analysis suggested that the target gene of the HCNE within FTO was IRX3 and using sequences from the obesity associated FTO LD block in a zebrafish-based, GFP reporter assay found that expression patterns matched those of IRX3. As IRX3 is highly expressed in pancreas, they went on to suggest that at least some of the effect of the FTO locus upon susceptibility to type 2 diabetes may be through changes in insulin secretion.
Smemo et al. build upon these observations in a comprehensive study bringing together evidence from murine, human and in vitro studies to make a compelling case for the involvement of IRX3 in the association between human obesity and FTO (Smemo et al., 2014) .
They initially investigated cis-regulatory interactions between FTO and IRX3 using chromatin conformation capture in both embryonic (mice and zebrafish) and brain tissue from adult mice. The authors found the promoter of Irx3 strongly interacted with the obesityassociated interval within FTO (Fig 1A) .
Results from an in vivo mouse reporter assay which tested human DNA fragments from the FTO obesity-associated region, plus data from studies using a human bacterial artificial chromosome (BAC) spanning the FTO locus that included its promoter and the obesityassociated region, clearly showed that IRX3 relied on long-range regulatory input from FTO.
Building upon this, a crucial data set missing from previous studies looked at gene expression levels in the cerebellum, a site of high expression of both FTO and IRX3. This eQTL mapping in human brain samples demonstrated that obesity-linked SNPs such as rs9930506 were associated with IRX3 expression, but not with expression of FTO, thereby directly linking these variants to IRX3 regulation (Fig 1B) .
Returning to mouse models, Smemo reported that Irx3 null mice had a significant reduction in body weight, with less fat and lean mass compared to wild type controls. Transcriptional analysis of tissue indicated that there may be increased sympathetic tone to white adipose tissue as well as increased activation of brown adipose, leading to increased energy expenditure which contributes to the phenotype seen. Using Cre-lox technology to express a dominant-negative Irx3 only within the hypothalamus, this group determined that disrupting Irx3 function in this region alone recapitulated the metabolic phenotype of Irx3-deficient mice, thereby supporting the notion that hypothalamic Irx3 to be critical in the regulation of body composition.
While this appears to be a compelling set of data there are still some areas of uncertainty.
Cerebellum is not an area of brain normally recognised to be involved in the control of energy expenditure and eQTL analysis using hypothalamic tissue seems to be an important next step. Further, it would be very interesting to determine if overexpression of Irx 3, either globally or in a more tissue specific manner, causes obesity in a model organism.
Nevertheless, it would appear that IRX3 is a strong candidacy to be a major mediator of the effects of the common intronic SNPs on human adiposity.
Discussion
The technological and computational advances that underpin genetic association studies have brought forth a glut of new information relevant to a whole host of different human phenotypes, complex traits and disease conditions. They have much potential to reveal previously unanticipated insights but powerful as the data generated are, there remains the need to move from an association map into a systems, models and platforms that can be used as tools to get to grips with the biological architecture of the problem under scrutiny.
So, seven years on from the initial cluster of reports, how far have we come with the poster boy of metabolic GWAS?
The data set from animal studies make a decent case that FTO has a role in the control of Taken in isolation, the data on FTO from human studies fall some way short from making compelling case for FTO as a candidate mediator of the obesity association. As described above, the most deleterious mutation has been identified in a single extended family with a multisystem phenotype that caused significant morbidity and early mortality. To date, there appears to be no reports of the deleterious encoding IRX3 mutations being found in populations of lean or obese; these would be a welcome addition to the field.
Can we learn wider lessons on how to tackle the ever growing list of "hits" from metabolically relevant association studies? Although murine models have proven invaluable on the study of monogenic disorders of energy balance and appetitive behaviour, it is naïve to assume that murine models alone can give us all the answers. A comprehensive perspective which clearly lays out many of the issues surrounding the determination of pathogenicity (or otherwise) of genetic variance can be found in a recent article by MacArthur and colleagues, where the primacy of robust genetic support for causation is rightly emphasised (MacArthur et al., 2014) . Further, the recent paper by Smemo highlighting the role of IRX3 is an exemplar of how a multi-layered combination of techniques and evidence need to be marshalled together (Smemo et al., 2014) . The eQTL data presented are key pieces of evidence and in the future when determining if non-coding SNPs are exerting a functional impact through the alteration of gene expression, a stronger emphasis on eQTL mapping seems a sensible step forward. Material contained with the GtEX dataset, for example, where a larger number of human tissues have been used for eQTL mapping (http://www.gtexportal.org/home/) is likely to be a valuable resource.
Many of the strongest signals coming from GWAS spotlight genetic loci located some distance from coding exons. Sticking a pin in the nearest named coding sequence and studying the consequence of loss of that gene is one very simple way to move forward. But if we are to learn anything from the iterative process that the FTO story has been to date, it is that it is only by embracing all the technologies at our disposal will we be able to move from GWAS signals to biological understanding . mapping demonstrates an association of obesity linked SNPS with IRX3 expression.
